High importance
Aug 19, 2026
To evaluate the prevalence and clinical implications of Hereditary Hemorrhagic Telangiectasia (HHT) in relation to the genes involved (ALK1, endoglin, SMAD4) and treatment modalities (bevacizumab, pomalidomide) for associated arteriovenous malformations.
This study involves a comprehensive review of existing literature on HHT, alongside an analysis of genetic mutations linked to the disease and assessment of treatment efficacy using bevacizumab and pomalidomide in patients with arteriovenous malformations.
The findings indicate that HHT is underdiagnosed, with a significant portion of the population being unaware of their condition. Genetic markers (ALK1, endoglin, SMAD4) were found to be crucial in diagnosing and managing HHT. Treatment with bevacizumab and pomalidomide has shown promising results in reducing symptoms and complications from arteriovenous malformations.
The research is constrained by the variability in diagnostic criteria for HHT and the lack of large-scale, multicentric clinical trials to validate findings on treatment efficacy and genetic screening.
Recognizing HHT as a more prevalent condition than previously thought could lead to improved screening, earlier diagnosis, and better management of patients, ultimately reducing complications from arteriovenous malformations and enhancing patient quality of life.